Recently, a research team from the Wuhan Institute of Virology, Chinese Academy of Sciences, has made significant progress in antiviral drug development by identifying a novel compound that effectively inhibits Nipah virus. Nipah virus is a highly pathogenic zoonotic virus capable of causing severe encephalitis and respiratory illness, with a fatality rate ranging from 40% to 75%. Currently, no approved therapeutics or vaccines are available. Using a high-throughput screening platform, the team identified a small-molecule compound named ‘WIV-101’ from thousands of candidates. In vitro experiments demonstrated that WIV-101 potently blocks Nipah virus replication with low cytotoxicity to host cells. Further animal studies showed that infected hamsters treated with WIV-101 exhibited significantly higher survival rates and reduced viral loads. The researchers noted that this discovery provides a promising lead compound for developing clinical treatments against Nipah virus and lays groundwork for combating other pathogens in the Henipavirus genus. The findings have been published in the prestigious journal Nature Communications, and the team plans to proceed with preclinical safety and pharmacokinetic evaluations.
近日，中国科学院武汉病毒研究所的研究团队在抗病毒药物研发方面取得重要进展，发现一种新型化合物对尼帕病毒（Nipah virus）具有显著抑制作用。尼帕病毒是一种高致病性人畜共患病毒，可引发严重脑炎和呼吸道疾病，病死率高达40%至75%，目前尚无获批的特效药物或疫苗。研究团队通过高通量筛选平台，从数千种候选分子中鉴定出一种名为“WIV-101”的小分子化合物，该化合物在体外实验中能有效阻断尼帕病毒的复制过程，且对宿主细胞毒性较低。进一步的动物模型实验显示，接受WIV-101治疗的感染仓鼠存活率显著提高，病毒载量明显下降。研究人员表示，这一发现为开发针对尼帕病毒的临床治疗药物提供了重要候选分子，也为应对其他亨尼帕病毒属（Henipavirus）病原体奠定了基础。目前，该成果已发表于国际权威期刊《自然·通讯》，并计划开展后续的临床前安全性评估与药代动力学研究。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22552.html